Purpose: Castration-sensitive prostate cancer (CSPC) is a complex and heterogeneous
condition encompassing a range of clinical presentations. As new approaches have …

Prostate cancer may recur several years after definitive treatment, such as prostatectomy or
radiation therapy. A rise in serum prostate-specific antigen (PSA) level is the first sign of …

Rising prostate specific antigen (PSA) levels may occur in men with prostate cancer (PCa)
who undergo whole-gland treatment with curative intent. The reported percentage of …

The optimal therapy for patients with non-metastatic biochemically relapsed prostate cancer
(BRPC-M0) after local therapy is elusive. Thus, the evaluation of new non-toxic compounds …

Purpose This is a first-in-human study to evaluate the radiation dosimetry of a new prostate-
specific membrane antigen (PSMA)-targeted radiopharmaceutical,[18F] AlF-P16-093, and …

PARP is a nuclear enzyme with a major function in the DNA damage response. PARP
inhibitors (PARPi) have been developed for treating tumors harboring homologous …

Tumor cells disseminate in various distant organs at early stages of cancer progression.
These disseminated tumor cells (DTCs) can stay dormant/quiescent without causing patient …

ABSTRACT Background and Objective: Salvage robot assisted radical prostatectomy
(sRARP) is performed for patients with biochemical or biopsy proven, localized prostate …

Abstract Background Prostate cancer (PCa) is one of the leading causes of cancer death in
men. About 30% of PCa will develop a biochemical recurrence (BCR) following initial …

Background A consensus has not been reached on the value of prostate-specific antigen
density (PSAD) as a predictor of biochemical recurrence of prostate cancer. This meta …